Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma

被引：0
|
作者：
Latimer, Nicholas [1 ]
Amonkar, Mayur [2 ]
Stapelkamp, Ceilidh [3 ]
Sun, Peng [2 ]
机构：
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[2] GlaxoSmithKline, Collegeville, PA USA
[3] GlaxoSmithKline, Uxbridge, Middx, England
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT330
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma
    Latimer, Nicholas R.
    Amonkar, Mayur M.
    Stapelkamp, Ceilidh
    Sun, Peng
    MELANOMA RESEARCH, 2015, 25 (06) : 528 - 536
  • [2] Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
    Dummer, Reinhard
    Long, Georgina V.
    Robert, Caroline
    Tawbi, Hussein A.
    Flaherty, Keith T.
    Ascierto, Paolo A.
    Nathan, Paul D.
    Rutkowski, Piotr
    Leonov, Oleg
    Dutriaux, Caroline
    Mandala, Mario
    Lorigan, Paul
    Ferrucci, Pier Francesco
    Grob, Jean Jacques
    Meyer, Nicolas
    Gogas, Helen
    Stroyakovskiy, Daniil
    Arance, Ana
    Brase, Jan C.
    Green, Steven
    Haas, Tomas
    Masood, Aisha
    Gasal, Eduard
    Ribas, Antoni
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1428 - +
  • [3] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Hashemi, Sayed M. S.
    Mazieres, Julien
    Kim, Tae Min
    Quoix, Elisabeth
    Souquet, Pierre-Jean
    Barlesi, Fabrice
    Baik, Christina
    Villaruz, Liza C.
    Kelly, Ronan J.
    Zhang, Shirong
    Tan, Monique
    Gasal, Eduard
    Santarpia, Libero
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
  • [4] Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (07): : 234 - 235
  • [5] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2016, 11 (03) : 417 - 428
  • [6] Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
    Atkinson, Victoria
    Sandhu, Shahneen
    Hospers, Geke
    Long, Georgina, V
    Aglietta, Massimo
    Ferrucci, Pier F.
    Tulyte, Skaiste
    Cappellini, Gian Carlo Antonini
    Soriano, Virtudes
    Ali, Sayed
    Poprach, Alexandr
    Cesas, Alvydas
    Rodriguez-Abreu, Delvys
    Lau, Mike
    de Jong, Egbert
    Legenne, Philippe
    Stein, Dara
    King, Brianna
    van Thienen, Johannes, V
    MELANOMA RESEARCH, 2020, 30 (03) : 261 - 267
  • [7] Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib
    Kromer, Christian
    Vlahova, Lyubomira D.
    Julius, Katharina
    Schnabel, Viktor
    Schoen, Michael P.
    Reuter-Jessen, Kirsten
    Seif Amir Hosseini, Ali
    Kretschmer, Lutz
    MELANOMA RESEARCH, 2022, 32 (02) : 124 - 127
  • [8] Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage IIIB/C BRAF V600 mutant melanoma
    Menzies, A. M.
    Gonzalez, M.
    Guminski, A.
    Nieweg, O.
    Shannon, K.
    Thompson, J. F.
    Kefford, R.
    Ch'Ng, S.
    Stretch, J.
    Spillane, A. J.
    Lee, J.
    Lee, H.
    Kapoor, R.
    Emmett, L.
    Rizos, H.
    Saw, R. P.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage iib/c BRAF-V600 mutation positive melanoma.
    Saw, Robyn
    Menzies, Alexander M.
    Guminski, Alexander
    Nieweg, Omgo E.
    Shannon, Kerwin F.
    Gonzalez, Maria
    Ch'ng, Sydney
    Kefford, Richard
    Thompson, John F.
    Stretch, Jonathan
    Spillane, Andrew J.
    Scolyert, Richard A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] COST PER OBJECTIVE RESPONSE WITH DABRAFENIB plus TRAMETINIB AS THE FIRST LINE OF TREATMENT IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600 MUTATION IN COLOMBIA
    Diaz-Ortega, M.
    Vergara, S.
    Montenegro, E.
    Barbosa, D.
    VALUE IN HEALTH, 2021, 24 : S31 - S31
12345